Tango Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Tango Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q2 2024.
  • Tango Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$25.6M, a 23.4% decline year-over-year.
  • Tango Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$116M, a 9.05% decline year-over-year.
  • Tango Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$102M, a 5.95% increase from 2022.
  • Tango Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$108M, a 85.8% decline from 2021.
  • Tango Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$58.2M, a 12.1% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$116M -$25.6M -$4.84M -23.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$112M -$37.9M -$9.91M -35.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-07
Q4 2023 -$102M -$30.8M -$1.7M -5.86% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$100M -$22.3M +$6.79M +23.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$107M -$20.7M +$4.15M +16.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$111M -$28M -$2.8M -11.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-07
Q4 2022 -$108M -$29.1M -$7.01M -31.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$101M -$29.1M -$9.46M -48.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$91.7M -$24.9M -$20.4M -453% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$71.3M -$25.2M -$13.1M -108% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$58.2M -$22M -$4.79M -27.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 -$53.4M -$19.6M +$7.21M +26.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$60.7M -$4.49M -$4.49M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-10
Q1 2021 -$56.2M -$12.1M -$4.19M -53% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-10
Q4 2020 -$52M -$17.3M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-28
Q3 2020 -$26.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$472* May 21, 2020 Jun 30, 2020 10-Q 2021-08-09
Q2 2020 -$8.39M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 -$7.91M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.